Immunogenic composition

Abstract

The present application relates to immunogenic compositions comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from S. aureus . Vaccines, methods of treatment using and processes to make an immunogenic composition comprising PNAG and Type 5 and/or 8 capsular polysaccharides are also described.

1 . An immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 capular polysaccharide or oligosaccharide from  S. aureus.    
     
     
         2 . The immunogenic composition of  claim 1  further comprising Type I, and/or Type II and/or Type III capsular polysaccharide or oligosaccharide from  S. epidermidis.    
     
     
         3 . The immunogenic composition of  claim 1  wherein the PNAG is derived from a staphylococcal bacterium. 
     
     
         4 . The immunogenic composition of  claim 1  further comprising a staphylococcal protein or fragment thereof. 
     
     
         5 . The immunogenic composition of  claim 4  wherein the staphylococcal protein or fragment thereof is an extracellular component binding protein selected from, the group consisting of laminin receptor, SitC/MntC/saliva binding protein, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin; ClfA, SdrC, SdrG, SdrH, Lipase GehD, SasA, FnbA, Cna; ClfB, FbpA, Npase, IsaAIPisA, SsaA, EPB, SSP-1, SSP-2, HBP, Vitronectin binding protein, fibrinogen binding protein, coagulase, Fig and MAP. 
     
     
         6 . The immunogenic composition of  claim 4  wherein the staphylococcal protein or fragment thereof is a transporter protein selected from the group consisting of Immunodominant ABC transporter, IsdA, 15 dB, Mg2+ transporter, SitC and Ni ABC transporter. 
     
     
         7 . The immunogenic composition of  claim 4  wherein the staphylococcal protein or fragment thereof is a toxin or regulator of virulence selected from the group consisting of alpha toxin (Hla), alpha toxin H35R mutant, RNA III activating protein (RAP). 
     
     
         8 . The immunogenic composition of  claim 4  comprising 2 or more staphylococcal proteins selected from at least 2 different groups selected from;
 a) at least one staphylococcal extracellular component binding protein or fragment thereof selected from the group consisting of laminin receptor, SitC/MntC/saliva binding protein, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrG, SdrH, Lipase GehD, SasA, FnbA, FnbB, Cna, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, Vitronectin binding protein, fibrinogen binding protein, coagulase, Fig and MAP; 
 b) at least one staphylococcal transporter protein or fragment thereof selected from the group consisting of Immunodominant ABC transporter, IsdA, IsdB, Mg2+ transporter, SitC and Ni ABC transporter; 
 c) at least one staphylococcal regulator of virulence, toxin or fragment thereof selected from the group consisting of alpha toxin (Hla), alpha toxin H35R mutant, RNA III activating protein' (RAP). 
 
     
     
         9 . The immunogenic composition of  claim 1  wherein a staphylococcal polysaccharide is conjugated to a protein carrier. 
     
     
         10 . The immunogenic composition of  claim 1  wherein the PNAG is conjugated to a protein carrier. 
     
     
         11 . The immunogenic composition of  claim 9  wherein the protein carrier comprises a staphylococcal protein or fragment thereof selected from the group consisting of laminin receptor, SitC/MntC/saliva binding protein, EbhA, EbhB, Elastin binding protein (EbpS), EFB (FIB), SBI, autolysin, ClfA, SdrC, SdrG, SdrH, Lipase GehD, SasA, FnbA, FnbB, Cna, ClfB, FbpA, Npase, IsaA/PisA, SsaA, EPB, SSP-1, SSP-2, HBP, Vitronectin binding protein, fibrinogen binding protein, coagulase, Fig, MAP, Immunodominant ABC transporter, IsdA, IsdB, Mg2+ transporter, SitC and Ni ABC transporter, alpha toxin (Hla), alpha toxin H35R mutant and RNA III activating protein (RAP). 
     
     
         12 . The immunogenic composition of  claim 9  wherein the protein carrier is selected from the group consisting of tetanus toxoid, diphtheria toxoid, CRMI97,  Haemophilus influenzae  protein D,  Pseudomonas aeruginosa  exoprotein A, pneumococcal pneumolysin and alpha toxoid. 
     
     
         13 . The immunogenic composition of  claim 1  wherein an effective immune response is generated against both  S. aureus  and  S. epidermidis.    
     
     
         14 . A vaccine comprising the immunogenic composition of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         15 . A method of making a vaccine comprising the steps of mixing antigens to make the immunogenic composition of  claim 1  and adding a pharmaceutically acceptable excipient. 
     
     
         16 . A method of preventing or treating staphylococcal infection comprising the step of administering the vaccine of  claim 14  to a patient in need thereof. 
     
     
         17 . A use of the immunogenic composition of  claim 1  in the manufacture of a vaccine for treatment or prevention of staphylococcal infection.